{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:58:05Z","timestamp":1770821885790,"version":"3.50.1"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>There have been concerns about the effects of antipsychotics on weight gain and the development of type 2 diabetes (T2DM). This article aims to provide an up-to-date review on the evidence addressing this issue and the practical implications for the management of people taking antipsychotics in the context of T2DM.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We carried out searches on MEDLINE\/PUBMED and the ClinicalTrials.gov website in August 2017 using the terms \u2018antipsychotic\u2019 and \u2018diabetes\u2019 or \u2018glucose\u2019 citing articles published after 2006 preferentially.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Antipsychotics are associated with T2DM and are likely to exert a causal effect of uncertain magnitude. Children and adolescents appear especially vulnerable to these metabolic effects; as T2DM is not common in healthy younger people, the relative risk is more apparent. Antipsychotics act on glucose and insulin homeostasis in a variety of direct and indirect mechanisms. To reduce the increasing health inequalities among individuals with mental illness screening, monitoring and prevention of T2DM is important, as is improved diabetes care in this population.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>It remains unclear whether these antipsychotic medications exacerbate an underlying predisposition to the development of T2DM or have a direct effect. Potential risks need to be weighed up and balanced between improved and lasting mental health benefits and any detrimental physical health side effects. Achieving parity of esteem between mental and physical health is a worldwide priority if we wish to improve life expectancy and quality of life in people with severe mental illness.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-18-0022","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T16:35:38Z","timestamp":1521563738000},"page":"R245-R258","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":36,"title":["Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation"],"prefix":"10.1093","volume":"178","author":[{"given":"Clare A","family":"Whicher","sequence":"first","affiliation":[{"name":"1Research and Development Department, Tom Rudd Unit, Moorgreen Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermione C","family":"Price","sequence":"additional","affiliation":[{"name":"1Research and Development Department, Tom Rudd Unit, Moorgreen Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I G","family":"Holt","sequence":"additional","affiliation":[{"name":"2Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"ref991","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/archgenpsychiatry.2009.79","article-title":"A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression","volume":"66","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in alzheimer\u2019s disease patients: the CATIE-AD study","volume":"166","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1041610213001658","article-title":"A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia","volume":"26","year":"2014","journal-title":"International Psychogeriatrics"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/070674371506001005","article-title":"Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study","volume":"60","year":"2015","journal-title":"Canadian Journal of Psychiatry"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2014.14020173","article-title":"The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial","volume":"172","year":"2015","journal-title":"American Journal of Psychiatry"},{"key":"ref1131","first-page":"12","article-title":"Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders","volume":"40","year":"2014","journal-title":"Current Health Sciences Journal"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.comppsych.2011.06.004","article-title":"Prevalence of diabetes in patients with major depressive disorder: a population-based study","volume":"53","year":"2012","journal-title":"Comprehensive Psychiatry"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bmj.317.7161.784","article-title":"Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/hex.12543","article-title":"Barriers and enablers of type 2 diabetes self-management in people with severe mental illness","volume":"20","year":"2017","journal-title":"Health Expectations"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow up of motality in patients with schizophrenia: a population based cohort study","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"ref691","first-page":"104","article-title":"Effect of age, family history of diabetes and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population based cross sectional study","volume":"3","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","article-title":"Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders","volume":"50","year":"2017","journal-title":"Clinical Biochemistry"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.2337\/dc13-0560","article-title":"Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/wps.20318","article-title":"The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity","volume":"15","year":"2016","journal-title":"World Psychiatry"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes obesity and dyslipidaemia","volume":"21","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","year":"2015","journal-title":"World Psychiatry"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08039488.2010.500397","article-title":"Swedish clinical guidelines -prevention and management of metabolic risk in patients with severe psychiatric disorders","volume":"64","year":"2010","journal-title":"Nordic Journal of Psychiatry"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.comppsych.2011.06.004","article-title":"Prevalence of diabetes in patients with major depressive disorder: a population-based study","volume":"53","year":"2012","journal-title":"Comprehensive Psychiatry"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","year":"2015","journal-title":"World Psychiatry"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.schres.2013.01.013","article-title":"Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial","volume":"146","year":"2013","journal-title":"Schizophrenia Research"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2014.203","article-title":"Diabetes mellitus and severe mental illness: mechanisms and clinical implications","volume":"11","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in alzheimer\u2019s disease patients: the CATIE-AD study","volume":"166","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","year":"2017","journal-title":"Drug Safety"},{"key":"ref841","first-page":"CD006617","article-title":"Aripiprazole versus typicals for schizophrenia","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","article-title":"A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults","volume":"30","year":"2014","journal-title":"Current Medical Research and Opinion"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JCP.0b013e31820fcea3","article-title":"Metabolic effects of olanzapine in patients with newly diagnosed psychosis","volume":"31","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.genhosppsych.2017.04.003","article-title":"Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis","volume":"47","year":"2017","journal-title":"General Hospital Psychiatry"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00125-017-4320-5","article-title":"Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive popoulation with schizophrenia: a nationwide nested case-control study","volume":"60","year":"2017","journal-title":"Diabetologia"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","year":"2010","journal-title":"Schizophrenia Research"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/070674371506001005","article-title":"Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study","volume":"60","year":"2015","journal-title":"Canadian Journal of Psychiatry"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","year":"2009","journal-title":"European Psychiatry"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","article-title":"Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders","volume":"50","year":"2017","journal-title":"Clinical Biochemistry"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","year":"2010","journal-title":"Clinical Psychiatry"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0269881105059505","article-title":"Do guidelines for severe mental illness promote physical health and well-being?","volume":"19","year":"2005","journal-title":"Journal of Psychopharmacology"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e0168549","DOI":"10.1371\/journal.pone.0168549","article-title":"The effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in adults with severe mental llness: a systematic review and meta-analysis","volume":"12","year":"2017","journal-title":"PLoS ONE"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0042-116313","article-title":"Can HbA1c be used to screen for glucose abnormalities among adults with severe mental illness?","volume":"125","year":"2017","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref771","first-page":"240","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","year":"2012","journal-title":"World Psychiatry"},{"key":"ref471","first-page":"593","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","year":"2014","journal-title":"Cell Press"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/wps.20318","article-title":"The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity","volume":"15","year":"2016","journal-title":"World Psychiatry"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/hex.12543","article-title":"Barriers and enablers of type 2 diabetes self-management in people with severe mental illness","volume":"20","year":"2017","journal-title":"Health Expectations"},{"key":"ref211","article-title":"More evidence of an association between antipsychotic drugs and the risk of diabetes in children and adolescents: a population-based study","volume":"18","year":"2015","journal-title":"Evidence-Based Mental Health"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/archgenpsychiatry.2009.79","article-title":"A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression","volume":"66","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41537-017-0018-4","article-title":"Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances","volume":"3","year":"2017","journal-title":"NPJ Schizophrenia"},{"key":"ref921","first-page":"e1059","article-title":"Differences in antipsychotic related adverse events in adukt, paediatric and geriatric populations","volume":"9","year":"2017","journal-title":"Cureus"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.schres.2013.01.013","article-title":"Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial","volume":"146","year":"2013","journal-title":"Schizophrenia Research"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41537-017-0018-4","article-title":"Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances","volume":"3","year":"2017","journal-title":"NPJ Schizophrenia"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevelance of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-anylsis of first epsiode, untreated and treated patients","volume":"39","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","article-title":"A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults","volume":"30","year":"2014","journal-title":"Current Medical Research and Opinion"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","article-title":"Obesity, serious mental illness and antipsychotic drugs","volume":"11","year":"2009","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"ref71","first-page":"240","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","year":"2012","journal-title":"World Psychiatry"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","year":"2010","journal-title":"Schizophrenia Research"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2012.03.017","article-title":"Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials","volume":"140","year":"2012","journal-title":"Schizophrenia Research"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0042-116313","article-title":"Can HbA1c be used to screen for glucose abnormalities among adults with severe mental illness?","volume":"125","year":"2017","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bmj.317.7161.784","article-title":"Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"ref431","first-page":"12","article-title":"Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders","volume":"40","year":"2014","journal-title":"Current Health Sciences Journal"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo controlled, randomized crossover study of the acute metabolic effects of olanzapine in health volunteers","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2014.14020173","article-title":"The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial","volume":"172","year":"2015","journal-title":"American Journal of Psychiatry"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement form the European Pyschiatry Association (EPA), supported by the European Association for the study of Diabetes (EASD) amd the European Society of Cardiology (ESC)","volume":"24","year":"2009","journal-title":"European Psychiatry"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevelance of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-anylsis of first epsiode, untreated and treated patients","volume":"39","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes obesity and dyslipidaemia","volume":"21","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second generation antipsychotic medications durimng first time use in children and adolsecents","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"121","DOI":"10.24869\/psyd.2017.121","article-title":"Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature","volume":"29","year":"2017","journal-title":"Psychiatria Danubina"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jamda.2008.08.005","article-title":"Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study","volume":"10","year":"2009","journal-title":"Journal of the American Medical Directors Association"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"e0168549","DOI":"10.1371\/journal.pone.0168549","article-title":"The effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in adults with severe mental llness: a systematic review and meta-analysis","volume":"12","year":"2017","journal-title":"PLoS ONE"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2337\/dc08-0368","article-title":"Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR)","volume":"31","year":"2008","journal-title":"Diabetes Care"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11530130-000000000-00000","article-title":"Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation","volume":"24","year":"2010","journal-title":"CNS Drugs"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","year":"2017","journal-title":"Drug Safety"},{"key":"ref1171","first-page":"593","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","year":"2014","journal-title":"Cell Press"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2012.03.017","article-title":"Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials","volume":"140","year":"2012","journal-title":"Schizophrenia Research"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1345\/aph.1L015","article-title":"Antipsychotics and diabetes: an age-related association","volume":"42","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","year":"2010","journal-title":"British Journal of Psychiatry"},{"key":"ref391","first-page":"2561","article-title":"Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients","volume":"32","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental illness","volume":"368","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement form the European Pyschiatry Association (EPA), supported by the European Association for the study of Diabetes (EASD) amd the European Society of Cardiology (ESC)","volume":"24","year":"2009","journal-title":"European Psychiatry"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref681","first-page":"140","article-title":"Position statement on management of hyperglycemia in type 2 diabetes American Diabetes Association and European Association for the Study of Diabetes","year":"2015","journal-title":"Diabetes Care"},{"key":"ref1381","first-page":"140","article-title":"Position statement on management of hyperglycemia in type 2 diabetes American Diabetes Association and European Association for the Study of Diabetes","year":"2015","journal-title":"Diabetes Care"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11530130-000000000-00000","article-title":"Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation","volume":"24","year":"2010","journal-title":"CNS Drugs"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","year":"2016","journal-title":"World Psychiatry"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08039488.2010.500397","article-title":"Swedish clinical guidelines -prevention and management of metabolic risk in patients with severe psychiatric disorders","volume":"64","year":"2010","journal-title":"Nordic Journal of Psychiatry"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow up of motality in patients with schizophrenia: a population based cohort study","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"ref1091","first-page":"2561","article-title":"Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients","volume":"32","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1345\/aph.1L015","article-title":"Antipsychotics and diabetes: an age-related association","volume":"42","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","year":"2010","journal-title":"British Journal of Psychiatry"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2013 pharmacological mechanisms","volume":"125","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jamda.2008.08.005","article-title":"Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study","volume":"10","year":"2009","journal-title":"Journal of the American Medical Directors Association"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo controlled, randomized crossover study of the acute metabolic effects of olanzapine in health volunteers","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JCP.0b013e31820fcea3","article-title":"Metabolic effects of olanzapine in patients with newly diagnosed psychosis","volume":"31","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref91","first-page":"37","article-title":"Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00125-017-4320-5","article-title":"Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive popoulation with schizophrenia: a nationwide nested case-control study","volume":"60","year":"2017","journal-title":"Diabetologia"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.genhosppsych.2017.04.003","article-title":"Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis","volume":"47","year":"2017","journal-title":"General Hospital Psychiatry"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","year":"2010","journal-title":"Clinical Psychiatry"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","year":"2016","journal-title":"World Psychiatry"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second generation antipsychotic medications durimng first time use in children and adolsecents","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2014.203","article-title":"Diabetes mellitus and severe mental illness: mechanisms and clinical implications","volume":"11","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","article-title":"Obesity, serious mental illness and antipsychotic drugs","volume":"11","year":"2009","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref461","first-page":"488","article-title":"Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone","volume":"53","year":"2012","journal-title":"Singapore Medical Journal"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1041610213001658","article-title":"A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia","volume":"26","year":"2014","journal-title":"International Psychogeriatrics"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental illness","volume":"368","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"ref911","article-title":"More evidence of an association between antipsychotic drugs and the risk of diabetes in children and adolescents: a population-based study","volume":"18","year":"2015","journal-title":"Evidence-Based Mental Health"},{"key":"ref791","first-page":"37","article-title":"Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0269881105059505","article-title":"Do guidelines for severe mental illness promote physical health and well-being?","volume":"19","year":"2005","journal-title":"Journal of Psychopharmacology"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2337\/dc08-0368","article-title":"Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR)","volume":"31","year":"2008","journal-title":"Diabetes Care"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","year":"2009","journal-title":"European Psychiatry"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"121","DOI":"10.24869\/psyd.2017.121","article-title":"Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature","volume":"29","year":"2017","journal-title":"Psychiatria Danubina"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2013 pharmacological mechanisms","volume":"125","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"ref1161","first-page":"488","article-title":"Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone","volume":"53","year":"2012","journal-title":"Singapore Medical Journal"},{"key":"ref1391","first-page":"104","article-title":"Effect of age, family history of diabetes and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population based cross sectional study","volume":"3","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref141","first-page":"CD006617","article-title":"Aripiprazole versus typicals for schizophrenia","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.2337\/dc13-0560","article-title":"Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"ref221","first-page":"e1059","article-title":"Differences in antipsychotic related adverse events in adukt, paediatric and geriatric populations","volume":"9","year":"2017","journal-title":"Cureus"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/178\/6\/EJE-18-0022.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-18-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:11:48Z","timestamp":1676391108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/178\/6\/R245\/6655278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":128,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/eje-18-0022","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}